Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CTH | P32929 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22770072 | 1.00 | ALDH1A1 (0.53) | ALDH1A1RAB9AKMT2ATSHRSMN1; SMN2 | |
| SCHEMBL22781369 | 1.00 | ALDH1A1 (0.53) | ALDH1A1RAB9AKMT2ATSHRSMN1; SMN2 | |
| SCHEMBL22159213 | 0.81 | CYP19A1 (0.43) | ALDH1A1RAB9AKMT2ASMN1; SMN2MAPT | |
| SCHEMBL22159210 | 0.81 | CYP19A1 (0.43) | ALDH1A1RAB9AKMT2ASMN1; SMN2MAPT | |
| SCHEMBL22159211 | 0.81 | CYP19A1 (0.43) | ALDH1A1RAB9AKMT2ASMN1; SMN2MAPT | |
| SCHEMBL17064750 | 0.80 | NPC1 (0.37) | RAB9AKMT2ASMN1; SMN2MAPTLMNA | |
| SCHEMBL17064753 | 0.80 | NPC1 (0.37) | RAB9AKMT2ASMN1; SMN2MAPTLMNA | |
| SCHEMBL17064749 | 0.80 | NPC1 (0.37) | RAB9AKMT2ASMN1; SMN2MAPTLMNA | |
| SCHEMBL18623270 | 0.80 | NPC1 (0.37) | RAB9AKMT2ASMN1; SMN2MAPTLMNA | |
| SCHEMBL26951405 | 0.80 | GPR3 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118994099-A | Isomyosmine fast synthesis method of (2) | 南通益昊药业有限公司 | 2024-11-22 | — | — | CN | disclosed |
| US-20230301341-A1 | COMPOSITIONS AND METHODS FOR SUBLINGUAL DELIVERY OF NICOTINE | Poviva Corp. (US) | 2023-09-28 | — | — | US | disclosed |
| WO-2023183227-A1 | COMPOSITIONS AND METHODS FOR SUBLINGUAL DELIVERY OF NICOTINE | Poviva Corp. (US) | 2023-09-28 | — | — | WO | disclosed |
| US-20230301341-A1 | COMPOSITIONS AND METHODS FOR SUBLINGUAL DELIVERY OF NICOTINE | Poviva Corp. (US) | 2023-09-28 | — | — | US | disclosed |
| US-11700875-B1 | Compositions and methods for sublingual delivery of nicotine | Poviva Corp. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11700875-B1 | Compositions and methods for sublingual delivery of nicotine | Poviva Corp. (US) | 2023-07-18 | — | — | US | disclosed |
| WO-2023004918-A1 | PREPARATION METHOD FOR SYNTHESIZING CHIRAL NICOTINE FROM CHIRAL TERT-BUTYL SULFINAMIDE | 深圳市真味生物科技有限公司 | 2023-02-02 | — | — | WO | disclosed |
| CN-113444070-A | Preparation method for synthesizing chiral nicotine from chiral tert-butyl sulfinamide | 深圳市真味生物科技有限公司 | 2021-09-28 | — | — | CN | disclosed |
| EP-3750885-A1 | COMPOUND HAVING BET INHIBITORY ACTIVITY AND PREPARATION METHOD AND USE THEREFOR | Shanghai Haihe Pharmaceutical Co., Ltd. (CN) | 2020-12-16 | — | — | EP | disclosed |
| EP-3750885-A1 | COMPOUND HAVING BET INHIBITORY ACTIVITY AND PREPARATION METHOD AND USE THEREFOR | Shanghai Haihe Pharmaceutical Co., Ltd. (CN) | 2020-12-16 | — | — | EP | disclosed |
| CN-111683932-A | Compound with BET inhibition activity, preparation method and application thereof | 上海海和药物研究开发有限公司 | 2020-09-18 | — | — | CN | disclosed |
| WO-2019154329-A1 | COMPOUND HAVING BET INHIBITORY ACTIVITY AND PREPARATION METHOD AND USE THEREFOR | 上海海和药物研究开发有限公司 | 2019-08-15 | — | — | WO | disclosed |
| US-20170044187-A1 | 1-(3-AMINOPROPYL) SUBSTITUTED CYCLIC AMINE COMPOUNDS, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2017-02-16 | — | — | US | disclosed |
| US-7989394-B2 | Substituted 1-(azolin-2-yl)-amino-2-aryl-1-hetaryl-ethane compounds | BASF SE (DE) | 2011-08-02 | — | — | US | disclosed |
| US-20090131256-A1 | Substituted 1-(azolin-2-yl)-amino-2-aryl-1-hetaryl-ethane Compounds | BASF SE (DE) | 2009-05-21 | — | — | US | disclosed |
| EP-2041089-A1 | SUBSTITUTED 1-(AZOLIN-2-YL)-AMINO-2-ARYL-1-HETARYL-ETHANE COMPOUNDS | BASF SE (DE) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008000834-A1 | SUBSTITUTED 1-(AZOLIN-2-YL)-AMINO-2-ARYL-1-HETARYL-ETHANE COMPOUNDS | BASF SE (DE) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131256-A1 | Substituted 1-(azolin-2-yl)-amino-2-aryl-1-hetaryl-ethane Compounds | AAAS, AIPL1, ATXN2 | ALDH1A1 1606/4885RAB9A 2816/4885KMT2A 594/4885 |
| US-20170044187-A1 | 1-(3-AMINOPROPYL) SUBSTITUTED CYCLIC AMINE COMPOUNDS, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | CCR5, CCR1, CCRL2 | ALDH1A1 297/4885RAB9A 3743/4885KMT2A 3127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.